RadnostixINIS +2.73% Gross Margin % is 48.38% as of Mar. 2026, which is 16% below its 10-year median of 57.28. The stock has 3 warning signs investors should review. Among 938 Drug Manufacturers companies, Radnostix ranks better than 62.69% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Radnostix's Gross Profit for the
three
months ended in Mar. 2026 was $1.15 Mil. Radnostix's Revenue for the
three
months ended in Mar. 2026 was $2.38 Mil. Therefore, Radnostix's Gross Margin % for the quarter that ended in Mar. 2026 was 48.38%.
The historical rank and industry rank for Radnostix's Gross Margin % or its related term are showing as below:
INIS'
s Gross Margin % Range Over the Past 10 Years
Min: 43.42 Med: 57.28 Max: 62.22
Current: 55.87
During the past 13 years, the highestGross Margin % of Radnostix was 62.22%. The lowest was 43.42%. And the median was 57.28%.
INIS's Gross Margin % is ranked better than 62.69% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs INIS: 55.87
Radnostix had a gross margin of 48.38% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Radnostix was 0.80% per year.
Radnostix (OTCPK:INIS) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Radnostix had a gross margin of 48.38% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Radnostix Gross Margin % Related Terms
Radnostix Gross Margin % Historical Data
* Premium members only.
The historical data trend for Radnostix's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INIS vs TLPH, IXHL, ZYBT: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radnostix Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radnostix's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Radnostix's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Radnostix (INIS) has a Gross Margin % of 48.38% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Radnostix and its competitors. This is 16% below median its historical median of 57.28. Over the past decade, Radnostix's Gross Margin % has ranged from 43.42 to 62.22. According to the industry distribution chart, Radnostix ranks #350 out of 938 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is Radnostix's Gross Margin % too high?
Radnostix's current Gross Margin % of 48.38% is 16% below median its 10-year median of 57.28. Over the past 10 years, this metric has ranged from a low of 43.42 to a high of 62.22. The Drug Manufacturers industry median Gross Margin % is 48.44. Radnostix's value of 48.38% is 0.1% below this industry median. Based on the distribution chart, Radnostix ranks #350 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Radnostix's Gross Margin % compare to TLPH and IXHL?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #350 out of 938 companies for Gross Margin %. This puts Radnostix in the upper half of its industry. The industry median Gross Margin % is 48.44. Radnostix's value of 48.38% is 0.1% below this benchmark. Historically, Radnostix's own Gross Margin % has ranged from 43.42 to 62.22 over the past decade. While the company's 10-year median is 57.28 vs. the industry median of 48.44, Radnostix has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radnostix's current Gross Margin % of 48.38% is 0.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Radnostix and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radnostix's current Gross Margin % is 48.38%, which is 16% below median its own 10-year median of 57.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 43.8% above its estimated fair value. The current Gross Margin % is 48.38%, which is 16% below median its 10-year median of 57.28 and 0.1% below the Drug Manufacturers industry median of 48.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Radnostix (INIS), the current Gross Margin % is 48.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INIS has been successfully added to your 